Flu infections expected to rise as new H1N1 strain emerges

The dominant H1N1 strain carries a mutation that may bypass immunity in young adults, while a mismatch with current vaccines reduces protection.

Flu infections expected to rise as new H1N1 strain emerges
Photo: The Guardian

Influenza has arrived early this year, and while the CDC considers activity to be low, infections are expected to rise in the coming weeks as the virus spreads through the Midwest and East Coast. So far, there have been 16,000 recorded flu-related hospitalizations.

The dominant strain this year is an H1N1 virus carrying a mutation known as G155E. Dr Amesh Adalja, an infectious disease specialist at the Johns Hopkins Center for Health Security, said there is no evidence the mutation makes the virus more likely to cause severe illness, though it resembles H1N1 strains from before 2009. Early research suggests teens and young adults under 25 have less immunity to this strain, as the virus may be more able to get around some of the immunity people have from prior infections and prior vaccinations.

The current vaccine is a weaker match against infection because the specific variant emerged after vaccine components were already chosen. Osterholm said the question is not about whether the vaccine works or does not work, but about it being less protective. He compared being vaccinated to having a seatbelt attached, noting it protects against severe disease, hospitalization, and death.

Moderna has made an mRNA-based flu vaccine, called mFlusiva, available to the public for the first time. It is recommended for adults 50 and older, a group facing the highest risk, and has shown to produce milder reactions than mRNA Covid vaccines. Dr Adalja said mRNA technology may help future vaccine strain selections occur closer to the start of flu season to improve the match.

Experts say now is the time to get vaccinated, especially for those under 25, as it takes about two weeks for the body to create enough antibodies. If people get sick, at-home antigen tests for influenza, flu A, flu B, and respiratory syncytial virus are available. Knowing the strain can help doctors prescribe antivirals like Tamiflu or Xofluza to reduce serious illness, hospitalizations, and recovery time.

Differences in how people respond to the flu relate more to the individual, such as those with diminished cardio respiratory capacity, than with the virus itself. Dr Alex L Greninger, head of the division of infectious disease diagnostics at the University of Washington, said flu can push people with recent heart disease over the edge in terms of heart and lung function.

Key facts

  • The dominant flu strain is an H1N1 virus with a G155E mutation.
  • The CDC has recorded 16,000 flu-related hospitalizations so far this season.
  • The current vaccine is a weaker match because the variant emerged after vaccine components were chosen.

Three perspectives

Neutral

The dominant H1N1 strain this year carries a mutation that provides a weaker match for the current vaccine.

Positive

The mRNA-based vaccine mFlusiva is available for adults 50 and older and has shown to produce milder reactions than mRNA Covid vaccines.

Negative

The current flu vaccine is less protective because the dominant variant emerged after the vaccine components were chosen.

Your week in news, every Wednesday

The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.

Choose your news coverage

Please choose and confirm your coverage.

All sections

Edition